openPR Logo
Press release

Neuropsychiatric Disorders and Treatment Market 2018 to 2023 | Expected to reach USD 2.95 Billion with Topmost Players Astrazeneca, GlaxoSmithKline, Pfizer, Wyeth and More

10-20-2018 12:29 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Neuropsychiatric Disorders and Treatment Market

Neuropsychiatric Disorders and Treatment Market

The Global Neuropsychiatric Disorders and Treatment Market Provide Detail Information about the Present and Forecasted Market with Its Key Players that Influences the Market on Global Scale.

Global Neuropsychiatric Disorders and Treatment Market – Scenario

Neuropsychiatric is the mental disorder occur due to disturbance in the function of cerebral system. Mania and hallucination are some of the major neuropsychiatric diseases. Increasing prevalence of different neuropsychiatric diseases across the globe is the major driving factor for the growth of the market.

While long term treatment and lack of clinical trial data for neuropsychiatric diseases may hamper the growth of the market. Global neuropsychiatric disorders and treatment market is expected to grow at a CAGR of 6.2% during forecasted period.

Sample Report @ https://www.marketresearchfuture.com/sample_request/1281

Global Neuropsychiatric Disorders and Treatment Market - Overview

Neuropsychiatric disorders are mental disorder occur due to disturbance in the function of cerebral system. Neuropsychiatric disorders are most common to the people having more than 65 year’s age. Increasing prevalence of neuropsychiatric disorders across the globe is the major reason for driving the market.

Beside this increasing demand for the better treatment and development in the healthcare sector are the major driving factor for the growth of the market. While lack of clinical trial data for neuropsychiatric drugs and long term treatment of this diseases may restrain the growth of the market.

Geographically, North America accounts for the largest market for the neuropsychiatric disorders and treatment which is slightly less than Europe. Huge population suffering from neuropsychiatric disorders in this region is the major reason for the development of the market. According to WHO the number of patients suffering from neuropsychiatric disorders will be doubled in next couple of decades due to increasing aging population in North America and Europe. Asia Pacific has the third leading market which is expecting a fastest growth in this market due to rapid development in healthcare sector and increasing demand for the better treatment of the neuropsychiatric disorders.

Global Neuropsychiatric Disorders and Treatment Market - Key Players

AstraZeneca (UK), GlaxoSmithKline (UK), Universal Health Services Inc. (US), Biogen (US), Boehringer Ingelheim GmbH (Germany), Eli Lilly (US), Bristol-Meyer Squibb (US), Johnson & Johnson (US), Pfizer (US), Wyeth (US), Otsuka Holdings Co. Ltd (Japan), Astellas Pharma Inc. (Japan) are some of the prominent players at the forefront of competition in the Global neuropsychiatric disorders and treatment Market and are profiled in MRFR Analysis.

Global Neuropsychiatric Disorders and Treatment Market – Segmentation

Global neuropsychiatric disorders and treatment market is segmented on the basis of disorders into degenerative diseases, neurotic disorders, psychosis and others. On the basis of treatments it is segmented as shock treatment, drug treatment, others and on the basis of end users it is hospitals, clinics, research centres and others

Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/1281

Global Neuropsychiatric Disorders and Treatment Market - Competitive Analysis

Many factors are fuelling the growth of the market. This has attracted many of the manufacturer for development of the market in this sector. Increasing in alliances amongst the leading player has helped to introduction of new and better treatment for the neuropsychiatric disorders.

AstraZeneca is a multinational pharmaceutical and biopharmaceutical company headquartered in UK. Recently AstraZeneca has completed its collaboration with National Institute of Mental Health. This collaboration will help to discover the new and better drug treatment for distressing condition. AstraZeneca has also collaborated with Vanderbilt Center for the Neuroscience Drug Discovery which aims to discover new drug for the treatment of neuropsychiatric disorders.

Universal Health Services is an American Fortune 500 company headquartered in US. It is one of the largest hospital management companies in US. Universal Health Services is a huge company with the revenues of nearly USD 9.7 billion with the profit of more than USD 600 million.

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies headquartered in Germany. In 2016, Boehringer Ingelheim is collaborated with Saniona. This collaboration aims to develop the new treatment for the patients suffering from schizophrenia.

Global Neuropsychiatric Disorders and Treatment Market - Regional Analysis

On regional basis, North America commands the largest share of global neuropsychiatric disorders and treatment market. Increasing prevalence of neuropsychiatric disorders and governmental support for the research and development of the medicines in this area are the major driving factor for the growth of the market in North America. Europe commands the second largest market followed by Asia Pacific. Asia Pacific is expected to grow at a fastest rate due to rapid development of the healthcare sector in this regions.

Get Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/1281

About US:    

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuropsychiatric Disorders and Treatment Market 2018 to 2023 | Expected to reach USD 2.95 Billion with Topmost Players Astrazeneca, GlaxoSmithKline, Pfizer, Wyeth and More here

News-ID: 1316302 • Views:

More Releases from Market Research Future

1 Hexene Market size, Scope, Growth Opportunities, Trends by Manufacturers and Forecast to 2032
1 Hexene Market size, Scope, Growth Opportunities, Trends by Manufacturers and F …
1-Hexene, a key chemical intermediate primarily used in the production of polyethylene, is experiencing a significant surge in demand globally. This demand is driven by several factors, including the growing need for high-density polyethylene (HDPE) and linear low-density polyethylene (LLDPE) in various industries such as packaging, construction, and automotive. The 1 Hexene Market is estimated at US$ 0.142 billion in 2024 and is forecasted to increase rapidly at a CAGR of
Hydroxypropyl Methylcellulose Capsules Market Surge to Witness Huge Demand at a CAGR of 9.40% during the forecast period 2032
Hydroxypropyl Methylcellulose Capsules Market Surge to Witness Huge Demand at a …
Hydroxypropyl Methylcellulose (HPMC) capsules are a popular choice in the pharmaceutical and nutraceutical industries due to their versatility, safety, and stability. These capsules are derived from cellulose, a natural polymer, and are widely used for encapsulating a variety of drugs, supplements, and vitamins. The HPMC capsules market has been experiencing steady growth over the years, driven by several key factors. Hydroxypropyl Methylcellulose Capsules Market was valued at USD 0.420 Billion in
Skincare Market Size, Share, Trends, Analysis, Demand 2023-2032
Skincare Market Size, Share, Trends, Analysis, Demand 2023-2032
The Skincare Market was valued at USD 7.15 Billion in 2022. It is forecasted to increase from USD 7.54 Billion in 2023 to USD 11.58 Billion by 2032, demonstrating a compound annual growth rate (CAGR) of 5.51% between 2023 and 2032. The comprehensive scope and research methodology of the Skincare Market report lay the foundation for a detailed and insightful analysis of the industry. The report's scope encompasses a broad spectrum,
Acesulfame Potassium Market Trends, Recent Developments and Technology, Size, Share, Future Growth, Forecast Research Report 2032 
Acesulfame Potassium Market Trends, Recent Developments and Technology, Size, Sh …
The wire and cable material market is a vital sector of the global economy, serving as the backbone for various industries, including telecommunications, energy, automotive, and construction. The market encompasses a wide range of materials used in the production of wires and cables, such as copper, aluminum, polymers, and insulating materials. Over the years, the market has witnessed significant evolution driven by technological advancements, regulatory changes, and shifting consumer preferences. The

All 5 Releases


More Releases for Neuropsychiatric

New Study Offers Detailed Insights on Paediatric Neuropsychiatric Disorders Trea …
Neuropsychiatry is concerned with study of mental disorders of nervous system that arises from overt function of cerebral system. Paediatric neuropsychiatry is a clinical discipline pertaining to the study of diagnosis and treatment of behavioural and psychiatric disorders in infants, children and adolescents. There are several factors which are hampering the functions of nervous system and cerebral function that lead to paediatric neuropsychiatric diseases. Paediatric neuropsychiatric disorders mainly caused due
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Researchmoz added Most up-to-date research on "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" to its huge collection of research reports. Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 Summary This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems,
Neuropsychiatric Disorders And Treatment Market: Sturdy Expansion CAGR of 6.2% b …
Market Research Future published a research report on “Neuropsychiatric Disorders And Treatment Market Research Report- Global Forecast To 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Global Neuropsychiatric Disorders And Treatment Market Research Report, By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis And Others), By Treatments (Shock Treatment, Drug Treatment, Others) By End Users (Hospitals, Clinics, Research Centers And Others) - Forecast Till 2023 Market Scenario: Neuropsychiatric is the
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 | Now A …
Researchmoz added Most up-to-date research on "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" to its huge collection of research reports. This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects. To Get Sample Copy of
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review and Therapeut …
Market Research Hub includes new market research report "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" to its huge collection of research reports. This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects. Request Free Sample